Polygenic contribution to cannabis use disorder shared with and independent of ADHD: a GWAS-by-subtraction approach

Abstract Cannabis use disorder (CUD) is a heterogeneous condition characterized by different patterns of comorbidity and clinical presentation, yet the genetic contributors to this heterogeneity remain poorly understood. CUD frequently co-occurs with attention-deficit/hyperactivity disorder (ADHD), reflecting, in part, their shared genetic liability. Distinguishing the genetic component of CUD that operates through ADHD from the component independent of ADHD may help clarify whether these two components differ in their association with substance-use phenotypes, psychiatric traits, and broader health outcomes. We applied genomic structural equation modeling–based GWAS-by-subtraction to large-scale ADHD and CUD genome-wide association studies to characterize these two CUD components and investigate their genetic and phenotypic association profiles. The ADHD-independent component accounted for approximately 35% of CUD SNP-based heritability and included three genome-wide significant loci. Although both components showed genetic correlations with substance dependence and risk-taking behaviors, they exhibited distinct patterns of genetic correlation with substance use phenotypes, other mental disorders, and health outcomes. In a phenome-wide association study of 114,410 Estonian Biobank participants, both genetic components were associated with multiple health conditions, but the ADHD-related genetic component generally showed larger effects. Across two clinical samples, polygenic score generated with both components further revealed distinct associations with the comorbidity between ADHD and substance use disorders (SUD). Both scores were associated with SUD among individuals without ADHD. In contrast, only the polygenic score for the ADHD-related component (PGSadhd) was associated with ADHD and comorbid ADHD and SUD, with the strongest association observed in the comorbid group. Mediation analysis further indicated that ADHD diagnosis accounted for approximately 20% of the association between PGSadhd and SUD. Together, these findings demonstrate that ADHD-related and ADHD-independent components of CUD have distinct genetic and phenotypic association profiles, suggesting that genetic heterogeneity may contribute to the clinical heterogeneity of SUD. This framework may help guide further research into the etiology and clinical presentation of the disorder.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-06
DOI
https://doi.org/10.21203/rs.3.rs-11569749/v1
Primary Topic
Genetic Associations and Epidemiology
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Polygenic contribution to cannabis use disorder shared with and independent of ADHD: a GWAS-by-subtraction approach

Kadri Kõiv, Bru Cormand, Christian Fadeuilhe, Hans Flinker Bisgaard et al.
2 links
Research Square
Genetic Associations and Epidemiology
preprint

Polygenic contribution to cannabis use disorder shared with and independent of ADHD: a GWAS-by-subtraction approach

Kadri Kõiv, Bru Cormand, Christian Fadeuilhe, Hans Flinker Bisgaard, Lara Grau‐López, Marta Ribasés A, Josep Antoni Ramos‐Quiroga, Judit Cabana‐Domínguez, Kelli Lehto, María Soler Artigas, Sílvia Amoretti, Laura Vilar‐Ribó, Natalia Llonga, Àlex G. Segura, Pau Carabí‐Gassol, Valeria Macias‐Chimborazo, Uxue Zubizarreta‐Arruti, Manuel Donato Rodríguez-Romero, Triinu Varvas, Vanesa Richarte, Skojo Matea, Corrales Montse, Fernàndez-Castillo Noèlia, Daigre Constanza, Ros-Cucurull Elena, Palma-Alvarez Raúl
preprint en

Abstract

Abstract Cannabis use disorder (CUD) is a heterogeneous condition characterized by different patterns of comorbidity and clinical presentation, yet the genetic contributors to this heterogeneity remain poorly understood. CUD frequently co-occurs with attention-deficit/hyperactivity disorder (ADHD), reflecting, in part, their shared genetic liability. Distinguishing the genetic component of CUD that operates through ADHD from the component independent of ADHD may help clarify whether these two components differ in their association with substance-use phenotypes, psychiatric traits, and broader health outcomes. We applied genomic structural equation modeling–based GWAS-by-subtraction to large-scale ADHD and CUD genome-wide association studies to characterize these two CUD components and investigate their genetic and phenotypic association profiles. The ADHD-independent component accounted for approximately 35% of CUD SNP-based heritability and included three genome-wide significant loci. Although both components showed genetic correlations with substance dependence and risk-taking behaviors, they exhibited distinct patterns of genetic correlation with substance use phenotypes, other mental disorders, and health outcomes. In a phenome-wide association study of 114,410 Estonian Biobank participants, both genetic components were associated with multiple health conditions, but the ADHD-related genetic component generally showed larger effects. Across two clinical samples, polygenic score generated with both components further revealed distinct associations with the comorbidity between ADHD and substance use disorders (SUD). Both scores were associated with SUD among individuals without ADHD. In contrast, only the polygenic score for the ADHD-related component (PGSadhd) was associated with ADHD and comorbid ADHD and SUD, with the strongest association observed in the comorbid group. Mediation analysis further indicated that ADHD diagnosis accounted for approximately 20% of the association between PGSadhd and SUD. Together, these findings demonstrate that ADHD-related and ADHD-independent components of CUD have distinct genetic and phenotypic association profiles, suggesting that genetic heterogeneity may contribute to the clinical heterogeneity of SUD. This framework may help guide further research into the etiology and clinical presentation of the disorder.

Research Square
Universitat Autònoma de Barcelona (ES), University of California San Diego (US), Vall d'Hebron Institut de Recerca (ES), Hospital Clínic de Barcelona (ES), Vall d'Hebron Hospital Universitari (ES), Institut d'Investigació Sanitària Acreditat Institut de Recerca - Hospital Universitari Vall d'Hebron (ES), University of Tartu (EE), Universitat de Barcelona (ES)
Ministerio de Ciencia, Innovación y Universidades, European Commission, Eesti Teadusagentuur, Institució Catalana de Recerca i Estudis Avançats, Ministerio de Sanidad, Servicios Sociales e Igualdad, Ministerio de Ciencia e Innovación, Plan Nacional sobre Drogas, HORIZON EUROPE Framework Programme, Agència de Gestió d'Ajuts Universitaris i de Recerca, Instituto de Salud Carlos III, European Regional Development Fund, Agencia Estatal de Investigación
Good health and well-being
Genetic Associations and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon